|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Tiwari RC, Murray T, Ghafoor A,
et al: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed: Cancer facts and
figures 2004. American Cancer Society. Atlanta, GA: 2004.
|
|
4
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi K and Hagiwara K: Epidermal
growth factor receptor (EGFR) mutation and personalized therapy in
advanced nonsmall cell lung cancer (NSCLC). Target Oncol. 8:27–33.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bria E, Bonomi M, Pilotto S, et al:
Clinical meta-analyses of targeted therapies in adenocarcinoma.
Target Oncol. 8:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ge W, Cao DD, Wang HM, Jie FF, Zheng YF
and Chen Y: Endostar combined with chemotherapy versus chemotherapy
alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer
Prev. 12:2705–2711. 2011.PubMed/NCBI
|
|
8
|
Du Y, Peyser ND and Grandis JR:
Integration of molecular targeted therapy with radiation in head
and neck cancer. Pharmacol Ther. 142:88–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koh PK, Faivre-Finn C, Blackhall FH and De
Ruysscher D: Targeted agents in non-small cell lung cancer (NSCLC):
clinical developments and rationale for the combination with
thoracic radiotherapy. Cancer Treat Rev. 38:626–640. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Folkman J: Antiangiogenesis in cancer
therapy - endostatin and its mechanisms of action. Exp Cell Res.
312:594–607. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Ge W, Hu K, et al: Endostar
down-regulates HIF-1 and VEGF expression and enhances the
radioresponse to human lung adenocarcinoma cancer cells. Mol Biol
Rep. 39:89–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ge W, Zheng Y, Zhang L, et al: Endostar
enhances the radioresponse on Lewis lung carcinoma by regulating
HIF-1α. Biomedical Engineering and Informatics (BMEI), 2011. 4th
International Conference. Ding YS, Peng YH, Shi R, et al: 3:(IEEE,
Shanghai). 1486–1490. 2011. View Article : Google Scholar
|
|
15
|
Marín-Hernández A, Gallardo-Pérez JC,
Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha
modulates energy metabolism in cancer cells by inducing
over-expression of specific glycolytic isoforms. Mini Rev Med Chem.
9:1084–1101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Winum JY, Rami M, Scozzafava A, Montero JL
and Supuran C: Carbonic anhydrase IX: a new druggable target for
the design of antitumor agents. Med Res Rev. 28:445–463. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yokota H, Guo J, Matoba M, et al: Lactate,
choline, and creatine levels measured by vitro 1H-MRS as prognostic
parameters in patients with non-small-cell lung cancer. J Magn
Reson Imaging. 25:992–999. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bonuccelli G, Tsirigos A, Whitaker-Menezes
D, et al: Ketones and lactate ‘fuel’ tumor growth and metastasis:
Evidence that epithelial cancer cells use oxidative mitochondrial
metabolism. Cell Cycle. 9:3506–3514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goetze K, Walenta S, Ksiazkiewicz M, et
al: Lactate enhances motility of tumor cells and inhibits monocyte
migration and cytokine release. Int J Oncol. 39:453–463.
2011.PubMed/NCBI
|
|
20
|
Yaligar J, Thakur SB, Bokacheva L, et al:
Lactate MRSI and DCE MRI as surrogate markers of prostate tumor
aggressiveness. NMR Biomed. 25:113–122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
22
|
Denko NC: Hypoxia, HIF1 and glucose
metabolism in the solid tumour. Nat Rev Cancer. 8:705–713. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Comerford KM, Wallace TJ, Karhausen J,
Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1
dependent regulation of the multidrug resistance (MDR1) gene.
Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
|
|
24
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Williams KJ, Telfer BA, Xenaki D, et al:
Enhanced response to radiotherapy in tumours deficient in the
function of hypoxia inducible factor-1. Radiother Oncol. 75:89–98.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masaki H, Okano Y and Sakurai H:
Generation of active oxygen species from advanced glycation
end-products (AGEs) during ultraviolet light A (UVA) irradiation
and a possible mechanism for cell damaging. Biochim Biophys Acta.
1428:45–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jagetia GC, Shetty PC and Vidyasagar MS:
Inhibition of radiation-induced DNA damage by jamun, Syzygium
cumini, in the cultured splenocytes of mice exposed to different
doses of γ-radiation. Integr Cancer Ther. 11:141–153. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sattler UG and Mueller-Klieser W: The
anti-oxidant capacity of tumour glycolysis. Int J Radiat Biol.
85:963–971. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sattler UG, Meyer SS, Quennet V, et al:
Glycolytic metabolism and tumour response to fractionated
irradiation. Radiother Oncol. 94:102–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quennet V, Yaromina A, Zips D, et al:
Tumor lactate content predicts for response to fractionated
irradiation of human squamous cell carcinomas in nude mice.
Radiother Oncol. 81:130–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hirschhaeuser F, Sattler UG and
Mueller-Klieser W: Lactate: a metabolic key player in cancer.
Cancer Res. 71:6921–6925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwasiborski PJ, Kowalczyk P, Mrówka P, et
al: Selected, biochemical markers of hypoxia. Przegl Lek.
69:115–119. 2012.(In Polish). PubMed/NCBI
|
|
33
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jain RK: Normalization of tumor
vasculature: An emerging concept of anti-angiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen QL, Meng MB, Yang B, et al: Endostar,
a recombined humanized endostatin, enhances the radioresponse for
human nasopharyngeal carcinoma and human lung adenocarcinoma
xenografts in mice. Cancer Sci. 100:1510–1519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du H, Ge W, Li C, Zhao Z, Xu X and Yang F:
Effects of rh-endostar in combination with radiotherapy on rats
with lung cancer. Zhongguo Fei Ai Za Zhi. 13:386–390. 2010.(In
Chinese). PubMed/NCBI
|
|
37
|
Xu M, Huang H, Xiong Y, Peng B, et al:
Combined chemotherapy plus endostar with sequential stereotactic
radiotherapy as salvage treatment for recurrent esophageal cancer
with severe dyspnea: A case report and review of the literature.
Oncol Lett. 8:291–294. 2014.PubMed/NCBI
|
|
38
|
Huang G and Chen L: Recombinant human
endostatin improves anti-tumor efficacy of paclitaxel by
normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res
Clin Oncol. 136:1201–1211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peng F, Xu Z, Wang J, et al: Recombinant
human endostatin normalizes tumor vasculature and enhances
radiation response in xenografted human nasopharyngeal carcinoma
models. PLoS One. 7:e346462012. View Article : Google Scholar : PubMed/NCBI
|
